Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
Interventions: glutamine, quality-of-life assessment, placebo; Drug · Other
Lead sponsor: Beth Faiman; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Smoking Lapse Behavior
Interventions: varenicline, bupropion, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Liraglutide, Oral Semaglutide, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hypertension, Hyperlipidemia
Interventions: Free Generic Samples (hydrochlorothiazide, simvastatin); Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Galactose; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pertussis, Whooping Cough
Interventions: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device; Combination Product
Lead sponsor: ILiAD Biotechnologies; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Cleveland, Ohio • Tomball, Texas • West Jordan, Utah

Conditions: Healthy
Interventions: PF-04447943; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Drug Induced Constipation
Interventions: Naloxegol, Diltiazem XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypertension
Interventions: Minocycline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 16 more

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts

Conditions: Obesity, Overweight
Interventions: NNC0487-0111 (formulation D), NNC0487-0111 (formulation C); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Rheumatoid Arthritis, Healthy Volunteers
Interventions: fostamatinib, rifampicin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions: amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride, thiotepa, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 16 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
Interventions: Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101; Procedure · Genetic
Lead sponsor: AviadoBio Ltd; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 3
States / cities: Columbus, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions: Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM; Genetic · Other
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers, Overweight
Interventions: Sucralose, Placebo; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
Interventions: 5 mg prednisone, 0 mg prednisone; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Osteopathic Manipulative Treatment; Procedure
Lead sponsor: Des Moines University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Des Moines, Iowa

Search by objective public record fields.

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

Study 3: Minocycline Decreases Microglia Activation

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Asthma and Osteopathic Manipulative Treatment